

FLUXICAP & FLUXI PFS

Flucloxacillin BP

Composition:

Fluxicap 250 capsule: Each capsule contains Flucloxacillin Sodium BP equivalent to Flucloxacillin 250 mg.

Fluxicap 500 capsule: Each capsule contains Flucloxacillin Sodium BP equivalent to Flucloxacillin 500 mg.

Fluxi powder for suspension: Each 5 ml of reconstituted suspension contains Flucloxacillin Sodium BP equivalent to Flucloxacillin 125 mg.

Pharmacology:

Flucloxacillin is isoxazolyl penicillin which combined the properties of resistance to hydrolysis by penicillinase, gastric acid stability and activity against gram-positive bacteria. Flucloxacillin is a bactericidal antibiotic that is particularly useful against penicillinase-producing staphylococci. Flucloxacillin kills bacterial cell wall, thus interfering with peptidoglycan synthesis. Peptidoglycan is a heteropolymeric structure that provides the cell wall with its mechanical stability. The final stage of peptidoglycan synthesis involves the completion of the cross-linking with the terminal glycine residue of the pentaglycin bridge linking to the fourth residue of the pentapeptide (D-alanine). The transpeptidase enzyme that performs this step is inhibited by Flucloxacillin. As a result the bacterial cell wall is weakened, the cell swells and then ruptures.

Indication:

Flucloxacillin is indicated for the treatment of infections due to Gram-positive organisms, including infections caused by beta-lactamase producing staphylococci.

Typical indications include:

Skin and soft tissue infections: boils, abscesses, carbuncles, furunculosis, cellulitis; infected skin conditions, e.g. ulcer, eczema and acne; infected wounds, infected burns, protection for skin grafts, otitis media and externa, impetigo.

Respiratory tract infections:

Pneumonia, lung abscess, empyema, sinusitis, pharyngitis, tonsillitis, and quinsy. Other infections caused by Flucloxacillin-sensitive organisms: osteomyelitis, enteritis, endocarditis, urinary tract infections, meningitis, septicaemia. Flucloxacillin is also indicated for use as a prophylactic agent during major surgical procedures where appropriate; for example, cardiothoracic and orthopaedic surgery.

Dosage & Administration:

Oral administration: Oral doses should be administered half to one hour before meals. Usual adult dosage (including elderly patients): 250 mg four times daily. In severe infections, dosage should be doubled. In osteomyelitis and endocarditis: up to 8 gm daily, in divided doses 6 to 8 hourly. In case of secondary bacterial infection in chicken pox: Flucloxacillin 500 mg six hourly should be prescribed.

Usual children dosage: 2-10 years : half of the adult dose. Under 2 years : quarter of the adult dose.

Contraindication:

Flucloxacillin is contraindicated in penicillin hypersensitive patients.

Side Effect:

Side effects as with other penicillin, are uncommon and mainly of a mild and transitory nature. Gastro-intestinal upsets (e.g. nausea, diarrhoea) and skin rashes have been reported. If skin rash occurs, treatment should be discontinued.

Precautions & Warnings:

Flucloxacillin should be used with caution in patients with evidence of hepatic dysfunction. Caution should also be exercised in the treatment of patients with an allergic diathesis.

Drug Interaction:

The administration of probenecid with Flucloxacillin results in higher serum peak concentrations and prolongs the time that therapeutic concentrations of Flucloxacillin are achieved in serum. Physical incompatibility and/or loss of activity of Flucloxacillin in solution has been reported when given with gentamycin sulphate, streptomycin sulphate, vitamin mixtures. Flucloxacillin should not be added to intravenous lipids, blood products and protein hydrolysates or other proteinaceous fluids.

Use In pregnancy & lactation:

The use of Flucloxacillin in pregnancy should be reserved for cases considered essential by the clinician. Use of the drug in the second and third trimesters may result in the sensitisation of the foetus. During lactation, trace quantities of penicillins can be detected in breast milk.

Storage:

Store in a cool and dry place. Protect from light and moisture.

Packaging:

Fluxicap 250 capsule: Each box contains 10 x 4's capsules in blister pack.

Fluxicap 500 capsule: Each box contains 8 x 7's capsules in blister pack.

Fluxi powder for suspension: Each bottle contains dry powder for preparation of 100 ml suspension.

Manufactured for

ZISKA Ziska Pharmaceuticals Ltd.
Kaliakoir, Gazipur, Bangladesh
By
Apex Pharma Ltd.
Shafipur, Gazipur, Bangladesh

Version: 01

P-02